OncoDNA

OncoDNA is a Belgium-based company founded in December 2012 and focused on precision medicine in oncology. Its stated purpose is to help individualize cancer treatment by analyzing the molecular characteristics of a patient’s tumor and translating those findings into information that can support therapeutic decision-making. The company operates at the intersection of oncology diagnostics, genomic analysis, clinical research, and personalized medicine. A central offering associated with OncoDNA is OncoDEEP, a targeted gene-sequencing approach used to investigate cancer-related genomic alterations. Rather than treating cancer solely according to its anatomical location or broad disease classification, molecular profiling seeks to identify mutations and other biological features that may influence prognosis, treatment selection, or eligibility for clinical trials. OncoDNA’s role has therefore included the provision of testing and analytical capabilities for clinicians, researchers, and oncology studies. The company became involved in the AURORA research program in April 2014. Conducted by the Breast International Group, AURORA is a multinational, multiyear effort focused on metastatic or locally relapsed breast cancer. OncoDNA was selected to use OncoDEEP for targeted gene sequencing in the program, which was initially expected to involve approximately 1,300 women and men treated at about 60 hospitals across 15 European countries. The project was designed both to improve understanding of metastatic disease and to support the development of treatments directed at specific molecular abnormalities. OncoDNA received Belgian innovation and entrepreneurship recognition in 2015. Ernst & Young named it a Promising Enterprise of the Year in Belgium, while the Deloitte Fast 50 jury recognized it as the Most Disruptive Innovator of 2015. These distinctions reflected the company’s positioning as an emerging biotechnology and precision-medicine venture rather than a conventional pharmaceutical manufacturer. In September 2016, OncoDNA raised EUR 7.7 million in private-equity financing. The round included historical shareholders—IPG/bio.be, Invest4OncoDNA, Sambrinvest, and Vinsovier—as well as new investors including Sofinim, an affiliate of Ackermans & van Haaren, SRIW, CPH, and Inventures. The financing provided additional capital for the company’s development, although the available reference material does not specify its detailed allocation or subsequent financial performance. The available public material identifies François Blondel as a member of OncoDNA’s board of directors. Beyond its Belgian base, the company’s participation in a research program spanning 15 European countries indicates an international operating and research footprint. Detailed information about its current ownership, management team, product portfolio beyond OncoDEEP, commercial revenues, present corporate structure, and current operating status is not established in the supplied sources.

OncoDNA was founded in Belgium in December 2012 with a focus on precision medicine in oncology. The company’s business concept was based on molecularly characterizing cancer samples so that clinicians could use tumor-specific biological information when considering treatment options. This placed OncoDNA within the emerging precision-oncology sector, where genomic testing and interpretation are used to complement conventional pathology and clinical assessment. One of the company’s identified technologies is OncoDEEP, a targeted gene-sequencing approach for cancer-related genomic analysis. The service was intended to detect molecular alterations relevant to oncology research and therapeutic decision-making. The available reference material does not provide a complete catalogue of OncoDNA’s products, laboratory infrastructure, regulatory clearances, or reimbursement arrangements, so its broader commercial portfolio cannot be described reliably. In April 2014, OncoDNA was selected to participate in AURORA, a multiyear research program led by the Breast International Group. AURORA focuses on metastatic or locally relapsed breast cancer and was initially planned to include about 1,300 patients treated in roughly 60 hospitals across 15 European countries. The program combines investigation of metastatic disease with research into treatments directed at particular molecular aberrations. OncoDNA’s role was to use OncoDEEP for targeted gene sequencing, giving the study a molecular-profiling component. The company received two forms of recognition in 2015. Ernst & Young in Belgium named it a Promising Enterprise of the Year in the context of its Entrepreneurs of the Year awards. Separately, the Deloitte Fast 50 jury selected OncoDNA as Most Disruptive Innovator of 2015. These awards helped establish its public profile as an innovative Belgian life-sciences company. In September 2016, OncoDNA completed a EUR 7.7 million private-equity financing round. The financing was subscribed by historical shareholders—IPG/bio.be, Invest4OncoDNA, Sambrinvest, and Vinsovier—and by a group of new investors comprising Sofinim, an affiliate of Ackermans & van Haaren, SRIW, CPH, and Inventures. The supplied source does not detail the company’s later fundraising, ownership changes, financial results, product expansion, or current corporate organization. François Blondel is identified as serving on OncoDNA’s board of directors. The company’s involvement in a major European oncology research program indicates that its activities extended beyond a purely domestic Belgian market. However, the available material is insufficient to establish a complete current executive roster, exact headquarters location, present-day product range, or continuing status with confidence.

• 2016

  EUR 7.7 million private-equity financing

  [1]OncoDNAen.wikipedia.org

  The company raised EUR 7.7 million from existing shareholders and a group of new investors.

• 2015

  Recognition as a promising and disruptive innovator

  [1]OncoDNAen.wikipedia.org

  Ernst & Young recognized OncoDNA as a Belgian Promising Enterprise of the Year, while Deloitte’s Fast 50 jury named it Most Disruptive Innovator of 2015.

• 2014

  Participation in the AURORA program

  [1]OncoDNAen.wikipedia.org

  OncoDNA was selected for the Breast International Group’s AURORA research program on metastatic and locally relapsed breast cancer, contributing targeted sequencing through OncoDEEP.

• 2012

  OncoDNA founded in Belgium

  [1]OncoDNAen.wikipedia.org

  OncoDNA was established in December 2012 as a company focused on precision medicine and molecular profiling in oncology.

A precision-oncology company providing tumor molecular profiling and genomic analysis to support individualized treatment decisions and oncology research.

• Targeted cancer gene sequencing

  OncoDEEP

  OncoDEEP is a targeted gene-sequencing approach used to analyze cancer-related molecular alterations. In the AURORA research program, it was used to support genomic characterization of breast-cancer samples. The available source presents OncoDEEP as a tool for oncology research and molecular profiling, but does not provide enough information to specify its current regulatory status, technical panel, clinical indications, or commercial availability.

• 2014AURORA breast-cancer research program

  Europe

  OncoDNA contributed molecular profiling and targeted gene sequencing through OncoDEEP to the Breast International Group’s multinational AURORA program, which addressed metastatic or locally relapsed breast cancer.

  Outcome. The program was planned to involve approximately 1,300 patients at about 60 hospitals in 15 European countries. A final study outcome is not specified in the supplied material.

  Source

• 2016

  Private-equity financing roundOther

  Background

  OncoDNA sought additional capital as a developing precision-oncology company with research and molecular-profiling activities.

  Action taken

  The company raised EUR 7.7 million through a private-equity round subscribed by historical shareholders and new investors.

  Aftermath

  The available source confirms the financing and participating investors but does not report the subsequent use of funds or measurable business effects.

  Private-equity financing. EUR 7.7 million raised (September 2016)

  Source

• 2021.01.26

  Reported2021.01.26

  OncoDNA appoints Bernard Courtieu CEO[2]OncoDNA任命Bernard Courtieu为首席执行官finance.yahoo.com

  OncoDNA announced that it appointed Bernard Courtieu as Chief Executive Officer. It also named founder Jean-Pol Detiffe Chief Strategic & Innovation Officer, responsible for strategic alliances and business development.

• 2020.02.14

  Reported2020.02.14

  OncoDNA completes €19 million Series B financing[3]OncoDNA完成1,900万欧元B轮融资finanznachrichten.de

  OncoDNA announced that it had completed a €19 million Series B equity financing. The company said the funding would support international growth, software development and hiring.

Read more

1. 1OncoDNAen.wikipedia.org
2. 2OncoDNA任命Bernard Courtieu为首席执行官finance.yahoo.com
3. 3OncoDNA完成1,900万欧元B轮融资finanznachrichten.de